Synphilin-1 is a protein that in humans is encoded by the SNCAIPgene. SNCAIP stands for "synuclein, alpha interacting protein".
Synphilin-1 is a cytosolic protein first identified in 1999 as a novel binding partner of α-synuclein, localized within Lewy bodies in Parkinson's disease brain tissue. Experimental studies in mammalian cells and yeast demonstrated that co-expression of synphilin-1 with α-synuclein promotes the formation of cytoplasmic inclusions resembling Lewy bodies.
Structure
The SNCAIP gene encodes synphilin-1, a multi-domain protein with a complex structure integral to neuronal function and implicated in neurodegenerative diseases. Structurally, synphilin-1 is composed of approximately 919 amino acids and is characterized by several functional domains, notably including six ankyrin repeats and a central coiled-coil domain spanning residues 510–557. These domains are typical protein-protein interaction motifs, facilitating synphilin-1's ability to interact with partner proteins such as alpha-synuclein (SNCA). SNCAIP binds to the N-terminal region of SNCA, allowing synphilin-1 to play a role in the formation of cytosolic inclusions mimicking Lewy bodies, which are hallmark features of synucleinopathies. The ankyrin repeats provide scaffolding for additional protein interactions, while the coiled-coil domain is crucial for the association with alpha-synuclein and possibly other synaptic or vesicular components.
Function
SNCAIP encodes synphilin-1, a cytoplasmic protein that interacts with alpha-synuclein in neuronal tissue and is involved in a variety of physiological processes related to synaptic function and protein homeostasis. Synphilin-1 is developmentally localized to synaptic terminals and participates in the regulation of synaptic vesicle trafficking. It may act as a scaffold protein, contributing to cellular processes like protein degradation through the ubiquitin-proteasome system and autophagy. Experimental evidence suggests that binding of synphilin-1 to alpha-synuclein can modulate synaptic vesicle dynamics, potentially impacting neurotransmitter release and synaptic plasticity. Synphilin-1's cytoprotective effects include inhibiting mitochondrial dysfunction, reducing reactive oxygen species production, and promoting neuronal survival under certain conditions.
Ubiquitination
Synphilin-1 undergoes ubiquitination. Parkin (an E3 ligase) modifies synphilin-1 and, together with α-synuclein, promotes the formation of ubiquitin-positive inclusion bodies. Mutations in parkin gene disrupt this activity. Additional E3 ligases, including SIAH1 and SIAH2, also ubiquitinate synphilin-1, influencing whether the protein is directed to proteasomal degradation or accumulates in inclusions. Inclusions containing α-synuclein and synphilin-1 share features with aggresomes, which may act to sequester misfolded proteins and limit cellular toxicity.
Clinical significance
Clinically, synphilin-1 is heavily implicated in neurodegenerative diseases, particularly Parkinson's disease (PD). It serves as a major component of Lewy bodies—the pathological protein aggregates characteristic of PD—and contributes to the formation of these cytoplasmic inclusions. While wild-type synphilin-1 may help sequester potentially toxic protein aggregates, certain isoforms and mutants, such as synphilin-1A, are highly aggregation-prone and associated with neuronal toxicity and degeneration. Genetic variation and altered methylation of the SNCAIP gene are linked with increased vulnerability to PD and related synucleinopathies. Thus, synphilin-1 exerts complex effects on neuronal health, acting as both a potential protector and a contributor to disease pathology depending on its expression, isoform, and interaction context.
Beyond Parkinson's disease, synphilin-1 has recently been implicated in glioblastoma. Transcriptomic and single-cell RNA sequencing analyses identified SNCAIP among histone lactylation related genes upregulated in glioblastoma, with elevated expression correlating with poorer patient survival. This has raised interest in synphilin-1 as a potential biomarker in cancer biology.
12Shishido T, Nagano Y, Araki M, Kurashige T, Obayashi H, Nakamura T, etal. (January 2019). "Synphilin-1 has neuroprotective effects on MPP+-induced Parkinson's disease model cells by inhibiting ROS production and apoptosis". Neuroscience Letters. 690: 145–150. doi:10.1016/j.neulet.2018.10.020. PMID30316984.
↑Chung KK, Zhang Y, Lim KL, Tanaka Y, Huang H, Gao J, etal. (October 2001). "Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease". Nature Medicine. 7 (10): 1144–1150. doi:10.1038/nm1001-1144. PMID11590439.
↑Neystat M, Rzhetskaya M, Kholodilov N, Burke RE (June 2002). "Analysis of synphilin-1 and synuclein interactions by yeast two-hybrid beta-galactosidase liquid assay". Neurosci. Lett. 325 (2): 119–123. doi:10.1016/s0304-3940(02)00253-7. PMID12044636. S2CID11517781.
↑Nagano Y, Yamashita H, Nakamura T, Takahashi T, Kondo E, Nakamura S (Dec 2001). "Lack of binding observed between human alpha-synuclein and Bcl-2 protein family". Neurosci. Lett. 316 (2): 103–107. doi:10.1016/s0304-3940(01)02330-8. PMID11742726. S2CID54363210.
Neystat M, Rzhetskaya M, Kholodilov N, Burke RE (Jun 2002). "Analysis of synphilin-1 and synuclein interactions by yeast two-hybrid beta-galactosidase liquid assay". Neurosci. Lett. 325 (2): 119–123. doi:10.1016/S0304-3940(02)00253-7. PMID12044636. S2CID11517781.
